阿斯利康AstraZeneca plc (AZN) 2019年年度报告「LSE」.pdf

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2019We are a global,science-led,patient-focused pharmaceutical company and in this Annual Report we report on the progress we made in 2019 in pushing the boundaries of science to deliver life-changing medicines.What science can d

2、o.Next?Our strategic priorities are focused on delivering value to patients and society.Delivering growth and therapy area leadershipby supplying medicines that can transform care and ensuring that they reach patients who need them.Accelerating innovative sciencein search of solutions that prevent,t

3、reat,and even cure,some of the worlds most serious health challenges.Being a great place to workby living our Values and behaviours,delivering as an enterprise team and leading in sustainability.See Delivering growth from page 31.See Innovative science from page 25.See A great place to work:Employee

4、s from page 44 and Contributing to society from page 49.Front cover image:Antibody-drug conjugates(ADCs)ADCs are among the most exciting technologies for the treatment of cancer.AstraZeneca is developing novel ADC targets that include therapy-resistant tumours and cancer stem cells.We are building a

5、 library of payloads,and using our antibody engineering expertise for site-s?ecific con?ugation and next-generation ADCs.Use of termsIn this Annual Report,unless the context otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC and its consolidated entities.WelcomeCorporate

6、 GovernanceChairmans Introduction 96Corporate Governance Overview 97Board of Directors 98Senior Executive Team 100Corporate Governance Report 102Science Committee Report 113Nomination and Governance Committee Report 114Audit Committee Report 116Directors Remuneration Report 125Remuneration Policy 14